| NCT07110441 | Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers | RECRUITING | PHASE1 | 2025-08-26 | 2025-12 | 2025-11 |
| NCT06987968 | A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy | RECRUITING | PHASE2 | 2025-08-25 | 2025-11 | 2025-10 |
| NCT05874414 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | RECRUITING | PHASE1, PHASE2 | 2023-08-21 | 2026-10 | 2026-05 |
| NCT05900050 | Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® | RECRUITING | PHASE2 | 2023-07-02 | 2025-12 | 2025-10 |
| NCT05368935 | Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects | COMPLETED | PHASE1 | 2022-04-25 | 2022-09-09 | 2022-09-04 |
| NCT05116826 | Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients | COMPLETED | PHASE1 | 2021-11-05 | 2022-04-13 | 2022-04-08 |
| NCT04171752 | Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers | COMPLETED | PHASE1 | 2019-11-22 | 2020-03-30 | 2020-03-22 |
| NCT03985969 | Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin | COMPLETED | PHASE1 | 2019-09-23 | 2020-03-31 | 2020-03-15 |
| NCT03953456 | Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL) | TERMINATED | PHASE2 | 2019-08-16 | 2020-07-14 | 2020-03-11 |
| NCT03883607 | Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) | TERMINATED | PHASE2 | 2019-06-25 | 2020-06-16 | 2020-06-16 |
| NCT03844555 | Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients | COMPLETED | PHASE1 | 2019-02-28 | 2020-03-21 | 2020-03-15 |
| NCT03765671 | Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients | COMPLETED | PHASE1 | 2018-12-12 | 2019-06-14 | 2019-06-07 |
| NCT03124108 | Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid | COMPLETED | PHASE2 | 2017-04-05 | 2018-10-31 | 2018-10-31 |
| NCT02704403 | Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE3 | 2016-03 | 2020-10-28 | 2020-10-28 |
| NCT02142127 | Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers | COMPLETED | PHASE1 | 2014-04 | 2015-04 | 2014-06 |
| NCT02091310 | Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers | COMPLETED | PHASE1 | 2014-02 | 2015-02 | 2014-12 |
| NCT01694849 | Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2012-09 | 2015-12 | 2015-02 |
| NCT01474161 | Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505 | COMPLETED | PHASE1 | 2011-11 | 2012-11 | 2012-11 |
| NCT01271777 | Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity | COMPLETED | PHASE2 | 2011-01 | 2011-11 | 2011-11 |
| NCT01261494 | Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE2 | 2010-12 | 2011-06 | 2011-06 |
| NCT01275469 | Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. | COMPLETED | PHASE2 | 2009-06 | 2010-01 | 2009-12 |
| NCT01271751 | Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity | COMPLETED | PHASE2 | 2009-01 | 2009-11 | 2009-09 |